2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
11
Phase NA
10
Phase 3
8
Phase 1/2
8
Phase 1
8
Phase 4
1
Phase 2/3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
CNS
1
Conditions
Breast Neoplasms
117
Neoplasms
101
Prostatic Neoplasms
76
Carcinoma, Non-Small-Cell Lung
75
Colorectal Neoplasms
73
Carcinoma, Hepatocellular
67
Leukemia, Myeloid, Acute
58
Stomach Neoplasms
52
Neoplasm Metastasis
50
Lung Neoplasms
48
Precursor Cell Lymphoblastic Leukemia-Lymphoma
44
Pancreatic Neoplasms
40
Recurrence
36
Head and Neck Neoplasms
32
Rectal Neoplasms
30
Colonic Neoplasms
30
Leukemia
29
Multiple Myeloma
28
Ovarian Neoplasms
26
Lymphoma
25
Squamous Cell Carcinoma of Head and Neck
24
Hematologic Neoplasms
23
Melanoma
22
Urinary Bladder Neoplasms
20
Liver Neoplasms
20
Polycystic Ovary Syndrome
19
Myelodysplastic Syndromes
19
Lymphoma, Large B-Cell, Diffuse
19
Esophageal Neoplasms
19
Uterine Cervical Neoplasms
16
Interventions
Gefitinib
1
Erlotinib Hydrochloride
1
AZD3759
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2/3
×
Respiratory Tract Diseases
×
Clear all
NCT03653546
2025-09-10
BM
Alpha Biopharma (Jiangsu) Co., Ltd.
Phase 2/3
Completed
492 enrolled